ImmuneOncia Therapeutics, Inc. (KOSDAQ:424870)

Market Cap	645.98B
Revenue (ttm)	111.21M -83.0%
Net Income	-27.36B
EPS	-390.00
Shares Out	74.17M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	460,102
Average Volume	547,035
Open	8,730.00
Previous Close	9,010.00
Day's Range	8,450.00 - 8,790.00
52-Week Range	4,455.00 - 16,110.00
Beta	n/a
RSI	49.62
Earnings Date	n/a

About ImmuneOncia Therapeutics

ImmuneOncia Therapeutics, Inc., an immuno-oncology-centric biopharmaceutical company, develops immuno-oncology drugs for the treatment of cancer. It develops IMC-001, a human monoclonal antibody of the IgG1 type that targets PD-L1 an immunotherapy for cancer, which is in Phase II clinical trial for the treatment of NK/T cell lymphoma and solid cancer patients with high tumor mutation burden; and IMC-002, a human monoclonal antibody of the IgG4 type targeting human CD47, which is in Phase I a clinical trial for the treatment of solid cancers, su...

• Industry: Pharmaceutical Preparations
• Founded: 2016
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 424870

Financial Performance

In 2025, ImmuneOncia Therapeutics's revenue was 111.21 million, a decrease of -83.01% compared to the previous year's 654.54 million. Losses were -27.36 billion, 381.2% more than in 2024.